secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001193125-25-028188
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase appoints Mark Iwicki as CEO; founder Milton Werner resigns
---------------------------------------------------------------------

- Milton Werner resigned as CEO/board member effective Feb 13, 2025; will consult through May 13, 2025 at $44,583/month.
- Mark Iwicki appointed CEO, President and director effective Feb 14, 2025; base salary $710K, bonus up to 60%, options for 15.1M shares.
- Amit Munshi named independent Chair of the Board, replacing Roberto Bellini who remains a director.
- Company advancing IkT-001Pro in Phase 2b trial with $110M from October financing; new CEO has PAH expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525028188/0001193125-25-028188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525028188/d835160d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-028188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer